Press Releases

Pulmonary Drug Delivery Systems Market to Reach $47 Billion Through 2022

May 09, 2018

WELLESLEY, Mass., May 09, 2018–The rising prevalence of respiratory disorders is helping to fuel growth in the pulmonary drug delivery market, according to a report by BCC Research. For reference, pulmonary drug delivery is an alternative to oral drug delivery, having the advantage of consistency, ease of use and cost effectiveness.

The industry is expected to see a compound annual growth rate (CAGR) of 4.3% through 2022, when it could be worth $47.0 billion, according to the report Pulmonary Drug Delivery Systems: Technologies and Global Markets.

Major players in the market include 3M Pharmaceuticals, AstraZeneca, Cipla Ltd., Dr. Reddy’s Laboratories Inc., GlaxoSmithKline, Mylan, Novartis, Omron Corp., Pfizer Inc., Teva Pharmaceutical Industries and Vectura Group.

Research Highlights

  • Growth of COPD is a major driver of the market. The COPD market in North America is anticipating a CAGR of 4.4% through 2022 and a value of $7.2 billion. Meanwhile, in the Middle East and Africa, COPD will grow at a CAGR of 5.6% through 2022 and reach a value of $4.4 billion.
  • The global nebulizer market is anticipating a CAGR of 3.5% through 2022 and a value of $6.7 billion. This growth will be led by the Middle East and Africa, which anticipates a CAGR through of 4.2% and a 2022 value of $1.97 billion.
  • The dry powder inhalers market will be dominated by North America, with a 2022 value of $7.4 billion. Meanwhile, this industry’s growth will be fastest in the Asia-Pacific region, which anticipates a CAGR of 5.4%.

“The market for pulmonary drug delivery systems is witnessing growth due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses,” said Robert G. Hunter, BCC Research senior editor, healthcare. “Other factors driving growth of this market are the emergence of novel inhaler designs and the increased use of non-invasive drug delivery methods.”

Market Challenges Include Compliance Issues

While pulmonary drug delivery has wide applications in the treatment of major lung diseases, there are several issues which are challenging the market. Chief among those are compliance issues. Combination therapy can have negative compliance effects on individuals, with the inconvenience of taking different medications leading to administration schedule non-adherence. Also challenging the market is the need to form drug particles in a suitable size range, as therapeutic efficiency depends on distribution of aerosol into the target receptor.

Editors/reporters requesting analyst interviews should contact

Pulmonary Drug Delivery Systems: Technologies and Global Markets( HLC094C )
Publish Date:     

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.